Prevalence, Health Care Utilization, and Costs of Fibromyalgia, Irritable Bowel, and Chronic Fatigue Syndromes in the Military Health System, 2006-2010
| By Dorris, Joseph | |
| Proquest LLC |
ABSTRACT Objective: We compared prevalence, health care utilization, and costs over time for nonelderly adults diagnosed with fibromyalgia syndrome (FMS), irritable bowel syndrome (IBS), and chronic fatigue syndrome (CFS) in relation to timing of federal approvals for FMS drugs. Data Source: We used military health care claims from
INTRODUCTION
Medically unexplained physical symptoms (MUPS) are func- tional disorders without known etiology or structural cause. As reviewed elsewhere, there is no agreement on MUPS diag- nostic nosology or diagnostic criteria.1-4 Such disorders, char- acterized by symptom clusters, are commonly referred to as psychosomatic disorders, or viewed as mood disorders with comorbid pain, gastrointestinal syndromes, or profound fatigue.4-6 Numerous reports document the concurrence of mood disorders and MUPS,7-12 but there is little empirical evidence for psychological etiology.13
Three common MUPS conditions are fibromyalgia syn- drome (FMS), irritable bowel syndrome (IBS), and chronic fatigue syndrome (CFS). The exact prevalence of these condi- tions is unknown but 2% of the U.S. population are estimated to have a FMS diagnosis,14,15 at least 10% are assumed to have IBS,16,17 and 0.4% are estimated to have CFS.18 Com- pared to civilian populations, higher rates of CFS19 and FMS have been reported among U.S. military veterans deployed to the Persian Gulf during the 1991 Gulf War.20 Such health conditions have long been recognized by the U.S. military as impacting readiness and job productivity.21
MUPS conditions are of interest to health care systems because of high health care utilization and costs.22,23 High costs are attributed to the number of diagnostic tests and procedures needed to rule out other conditions,24,25 comor- bid conditions that complicate diagnostic evaluations,23,25-27 and number of drug prescriptions.23,25,28-31 Medications contributing to high FMS costs include antidepressants,23,32 anxiolytics, nonsteroidal anti-inflammatory drugs, gabapentin, pregabalin, and duloxetine.33 Since the
Study Purpose
As part of an internal
METHODS
Data Source and Definitions
Procedures for data extraction of administrative claims data from the Military Health System Data Repository conformed to guidelines established by the
Definitions of Outcome Variables
Prevalence was derived by the yearly proportion of the beneficiary population who submitted claims with a pri- marydiagnosisofFMS,IBS,orCFS,andmetourinclu- sion criteria.
Health care utilization was measured by the number of ambulatory encounters per person per fiscal year. Ambula- tory encounters included any services or procedures provided in outpatient clinics, hospital outpatient departments, emer- gency departments, or ambulatory surgical facilities.
All encounters were included in the analysis even if the encounter did not specify a MUPS diagnosis. Costs were standardized to 2010 dollars. Total cost data were based on claims paid by DoD for ambulatory encounters, inpatient stays, ancillary costs (i.e., radiology, pathology/laboratory), filled prescriptions, facility costs, and professional services. Costs incurred in military treatment facilities were standard- ized using published 2010 DoD "Green Book" rates, which contain a 50/50 contribution split of Operations & Manage- ment, and military personnel rates. Costs incurred in civilian facilities were standardized using
Definitions of Explanatory Variables
Age was grouped into four categories: 18 to 24, 25 to 34, 35 to 44, and 45 to 64 years. Although age was analyzed with both continuous and categorical variables, we report on the categorical age values because they yielded similar patterns within the final models, and were more indicative of groupwise patterns than the continuous effect of age, linear or nonlinear.
Beneficiary category refers to the type of sponsor or family member eligible for DoD health care coverage. Spon- sors are active duty or military retired personnel from the
Service affiliation is the sponsor's branch of uniformed services, categorized as
Health care system refers to use of military treatment facilities (MTF) or civilian facilities. Comparisons between the systems were restricted to beneficiaries who used the military system only and the civilian system only.
Prime versus non-Prime reflects the type of beneficiary enrollment in
Within
Statistical Analysis
Using SAS software version 9.2 (
Stata software version 10.1 (
RESULTS
Prevalence
The number of MUPS cases for the selected conditions steadily increased in 5 years, from 20,585 (total population N = 4,936,721) to 33,654 (total population N = 5,183,395). Eighty percent of MUPS cases were female and this per- centage remained stable over time. Figure 1 shows FMS prevalence rates, based on the number of beneficiaries for each year. Between 2006 and 2007, the prevalence rate increased 0.026%; between 2007 and 2008, the prevalence rate increased 0.070%. Prevalence rates for IBS and CFS negligibly increased in a smooth projection over the 5 years. The correlations of determination for the prevalence rates over time indicate strong correlations between the number of cases and time for FMS and CFS cases; for IBS, only a moderate association was found.
The FMS prevalence trend analysis (Table I), controlling for demographic variables, found the highest prevalence among the 45 to 64 age group, females, and those affiliated with the
The IBS model showed significantly higher prevalence compared to the reference groups for females ( p < 0.001, 95% CI [0.113,0.129]); 25 to 34 age group(p < 0.001,95% CI [0.058, 0.082]), 35 to 44 age group ( p < 0.001, 95% CI [0.071, 0.096]), and 45 to 64 age group ( p < 0.001, 95% CI [0.089, 0.111]);
The CFS model showed highest prevalence rates among the 45 to 64 age group ( p < 0.001, 95% CI [0.008, 0.016]), females ( p < 0.001, 95% CI [0.006, 0.012]),
Health Care Utilization
Among beneficiaries who used civilian systems only, the number of FMS cases increased from 7,042 (2006) to 13,121 (2010) over 5 years. Among those who used military systems only, there was a little change in the number of FMS cases per year over time. For IBS, the number of civilian system only cases increased from 1,997 to 2,637 over 5 years, whereas the number of military system only cases decreased from 998 to 725 over 5 years. For CFS, there was a modest increase over time in the number of beneficiaries who used civilian system only (305-505), whereas the number using military treatment facilities only decreased (90 to 61).
The increase in average number of ambulatory encounters per person per year for FMS cases increased less for civilian care system (35.37 in 2006 to 39.01 in 2010) than for military care system (27.78 in 2006 to 33.72 in 2010). The average number of ambulatory encounters for IBS civilian system only cases increased from 22.58 to 26.52 over 5 years, whereas the corresponding number of military system only cases increased from 22.06 to 27.87. Among CFS civilian system only cases, the average number of annual encounters increased from 24.51 (2006) to 29.86 (2010); in contrast, military system only encounters had a sporadic pattern throughout the period.
Costs
Total inflation-adjusted cost for all beneficiaries diag- nosed with FMS increased from
Table II shows the results of the cost trend rate model for FMS cases. Controlling for other factors, subgroups with the highest costs per person were in the age group 25 to 34; females, whose total costs were, on average,
Among IBS cases, total cost increased from
Controlling for other factors, total cost per person trend rate model for IBS cases found higher per person costs in the 45 to 64 age group compared to the reference 18 to 24 age group by
Likewise, we found a significant increase in CFS cost over time with total cost increasing from
After controlling for other factors, higher costs for CFS cases was associated with the 25 to 34 age group compared to the reference age group ( p = 0.018, 95% CI [
Pharmacy Costs
Figure 3 shows pharmacy costs over time by MUPS condi- tion, with vertical hatched lines indicating the dates of
Total pharmacy costs for IBS cases were
Total 2006 and 2010 pharmacy costs for individuals diagnosed with CFS were
DISCUSSION
Data based on DoD health care claims provide an opportunity to examine population-based prevalence, utilization, and costs of MUPS conditions where equal benefits and access to care extend to all beneficiaries. Although military-related and civilian populations have differences in health status, our findings indicate the prevalence rates of U.S. nonelderly adults diagnosed with FMS, IBS, and CFS are 0.7%, 0.12%, and 0.02%, respectively. Prevalence rates for conditions coded with same ICD-9 codes should remain stable over time unless there are changes in diagnostic classification, biomed- ical advances, health risks, or environmental exposures. Indeed, prevalence rates for IBS and CFS remained relatively stable compared to FMS. The 2007 uptick in FMS rates cannot be attributed to diagnostic classification given the 1990-1992 diagnostic criteria for FMS were not modified until 2010.35 Likewise, there have been no medical break- throughs on FMS etiology, nor known changes in risk factors. Since the contemporary term "fibromyalgia" first appeared in 1981,36 the only risk factors associated with FMS have been female sex and middle age. Hence, we strongly suspect that the rise in FMS prevalence between 2006 and 2008 is due to drug marketing activities between
It should be noted that published conflicts of interest are also apparent in Cochrane reviews of FMS drugs. For exam- ple, the four authors of a 2013 Cochrane review examining the evidence for anticonvulsant drug use in FMS42 (e.g., pregabalin) have conflicts of interest with
Utilization of ambulatory services by DoD beneficiaries diagnosed with FMS, IBS, and CFS are at least five times higher than utilization for all conditions in the insured U.S. population,46 and at least four times higher than TRICARE Prime beneficiaries with medical-surgical ambulatory encounters.47 Among FMS cases, we found higher health care utilization in civilian facilities compared to military facilities. This latter finding was expected given the higher numbers of women and non-active duty beneficiaries diag- nosed with FMS, the majority of whom do not use military facilities. The unrestricted use of health care afforded to
In DoD, FMS-related total costs increased 93.5% between 2005 and 2010; for the same period, the National Health Expenditure rate for the U.S. population increased 27.9%.48 The 2010 average pharmacy cost per beneficiary diagnosed with FMS was
Most of the increase for FMS pharmacy costs is due to the three
Independent of our study, beginning in 2007, the DoD Pharmacoeconomics Center tracked FMS-approved drugs for their level of effectiveness compared to equivalent drugs and associated costs. In 2010, DoD classified milnacipran as a nonformulary drug, and in 2012 pregabalin and duloxetine were classified as nonformulary52 with equivalent drugs being provisionally required in newly diagnosed FMS cases. The minimal increase in FMS-related pharmacy costs between 2009 and 2010 appears to be a direct consequence of DoD evaluation of FMS drugs and cost containment efforts. It remains to be seen, however, if the nonformulary classification of these drugs will impact the prevalence, health care utilization, and overall costs related to FMS sub- sequent to 2010. In a
Limitations
We did not consider FMS comorbidities, nor establish the date of first FMS diagnosis as done elsewhere.23,29 We also did not control for severity of illness, or restrict health care utilization to encounters where MUPS was theprimarydiagnosis.Wehadnoinformationonsystem capacity, referrals to medical specialists, reason for pre- scribed medications, patient outcomes, or out-of-pocket expenses. Also, the doubling of FMS total costs in mili- tary settings may be due to an unknown number of active duty personnel given the diagnostic code of ICD-9 729.1 for conditions related to soft tissue and muscle strain and trauma. Finally, we could not determine if non-Prime enrollees submitted health care claims as completely as Prime enrollees.
Conclusion
Our study appears to be the first to compare the preva- lence, health care utilization, and costs over time of indi- viduals diagnosed with FMS to those diagnosed with IBS and CFS, and the first to examine these MUPS conditions in a military-connected population. Consistent with the liter- ature, we found disproportionate rates among middle-aged females, and higher average costs for women. Active duty personnel also incurred greater costs once controlling for other factors. Although we cannot establish causality, our findings strongly suggest that the DoD beneficiary popu- lation and their health care providers are susceptible to
REFERENCES
1. Spiegel BM, Farid M, Esrailian E, Talley J, Chang L: Is irritable bowel syndrome a diagnosis of exclusion?: a survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol 2010; 105(4): 848-58.
2. Kroenke K: Comparing fibromyalgia across different clinical settings: is it apples and oranges, or oranges and tangerines? Eur J Pain 2011; 15(9): 887-8, 999-1000.
3. Toda K: The term of functional somatic syndrome should be changed to the term of central sensitivity syndrome. Pain Practice 2012; 12(1): 83.
4. Christley Y, Duffy T, Martin CR: A review of the definitional criteria for chronic fatigue syndrome. J Eval Clin Pract 2012; 18(1): 25-31.
5. Agüera L, Failde I, Cervilla JA, Díaz-Fernández P, Mico JA: Medically unexplained pain complaints are associated with underlying unrecog- nized mood disorders in primary care. BMC Fam Pract 2010; 11: 17.
6. Klaus K, Rief W, Brähler E, Martin A, Glaesmer H, Mewes R: The distinction between "medically unexplained" and "medically explained" in the context of somatoform disorders. Int J Behav Med 2013; 20(2): 161-71.
7. Fietta P, Fietta P, Manganelli P: Fibromyalgia and psychiatric disorders. Acta Biomedic 2007; 78(2): 88 - 95.
8. Dansie EJ, Furberg H, Afari N, et al: Conditions comorbid with chronic fatigue in a population-based sample. Psychosomatics 2012; 53(1): 44-50.
9. Cella M, White PD, Sharpe M, Chalder T: Cognitions, behaviours and co-morbid psychiatric diagnoses in patients with chronic fatigue syn- drome. Psychol Med 2013; 43(2): 375-80.
10. Lackner JM, Ma CX, Keefer LA , et al: Type, rather than number, of mental and physical comorbidities increases the severity of symptoms in patients with irritable bowel syndrome. Clinical Gastroenterol Hepatol 2013; 11(9): 1147-57.
11. Maguen S, Madden E, Cohen B, Bertenthal D, Seal K: Association of mental health problems with gastrointestinal disorders in
12. Poeschla B, Strachan E, Dansie E, Buchwald DS, Afari N: Chronic fatigue and personality: a twin study of causal pathways and shared liabilities. Ann Behav Med 2013; 45(3): 289- 98.
13. Christley Y, Duffy T, Everall IP, Martin CR: The neuropsychiatric and neuropsychological features of chronic fatigue syndrome: revisiting the enigma. Curr Psychiatry Rep 2013; 15: 353.
14.
15. Painter JT, Crofford LJ, Talbert J: Geographic variation of chronic opioid use in fibromyalgia.
16. DiBonaventura M, Sun SX, Bolge SC, Wagner JS, Mody R: Health- related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr
17. Lovell RM, Ford AC: Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012; 107(7): 991-1000.
18. Jason LA, Porter N, Hunnell J, Rademaker A, Richman JA: CFS preva- lence and risk factors over time. J Health Psychol 2011; 16(3): 445 - 56.
19. Li B, Mahan CM, Kang HK,
20.
21. Edson JN, Ingegno AP, D'Albora JB: Irritable colon: experience with 122 cases in an
22. Nyrop KA, Palsson OS, Levy RL , et al: Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and func- tional abdominal pain. Aliment Pharmacol Ther 2007; 6(2): 237-48.
23. Berger A, Sadosky A, Dukes EM, Edelsberg J, Zlateva G, Oster G: Patterns of healthcare utilization and cost in patients with newly diag- nosed fibromyalgia. Am J Manag Care 2010; 16(5 Suppl): S126-37.
24. Haviland MG, Banta JE, Przekop P: Hospitalisation charges for fibro- myalgia in
25. Palacio A, Uribe CL, Li H , et al: Financial and clinical characteristics of fibromyalgia: a case-control comparison. Am J Manag Care 2010; 16(5 Suppl): S118-25.
26. Ladabaum U, Boyd E, Zhao WK, et al: Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. Clin Gastroenterol Hepatol 2012; 10(1): 37-45.
27. Lachaine J, Beauchemin C, Landry PA: Clinical and economic char- acteristics of patients with fibromyalgia syndrome. Clin J Pain 2010; 26(4): 284-90.
28. Chandran A, Schaefer C, Ryan K, Baik R, McNett M, Zlateva G: The comparative economic burden of mild, moderate, and severe fibromyal- gia: results from a retrospective chart review and cross-sectional survey of working-age U.S. adults. J Manag Care Pharm 2012; 18(6): 415-26.
29. Sanchez RJ, Uribe C, Li H , et al: Longitudinal evaluation of health care utilization and costs during the first three years after a new diagnosis of fibromyalgia. Curr
30. Longstreth GF, Wilson A, Knight K , et al: Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98(3): 600 -7.
31. Jason LA, Benton MC, Valentine L, Johnson A,
32. Reed C, Birnbaum HG, Ivanova JI, et al: Real-world role of tricyclic antidepressants in the treatment of fibromyalgia. Pain Pract 2012; 12(7): 533-40.
33. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D: Clinical comorbid- ities, treatment patterns, and healthcare costs among patients with fibro- myalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ 2012; 15(1): 19-31.
34. Barker KK: Listening to Lyrica: contested illnesses and pharmaceutical determinism. Soc Sci Med 2011; 73(6): 833 -42.
35. Wolfe F, Clauw DJ, Fitzcharles MA, et al: Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011; 38(6): 1113-22.
36. Treadwell BJ: Fibromyalgia. N Z Med J 1981; 94(690): 157-8.
37.
38. Kornfield R, Donohue J, Berndt ER, Alexander GC: Promotion of pre- scription drugs to consumers and providers, 2001-2010. PLoS One 2013; 8(3): e55504.
39.
40. Mease P, Berney S, Arnold L, et al: Fibromyalgia diagnostic and treat- ment challenges: Results from a recent summit of fibromyalgia experts.
41. Ablin J, Fitzcharles MA, Buskila D, Shir Y, Sommer C, Häuser W: Treatment of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines with special emphasis on complementary and alternative therapies. Evid Based Complement Alternat Med 2013; 2013: 485272.
42. Üçeyler N, Sommer C, Walitt B, Häuser W: Anticonvulsants for fibro- myalgia. Cochrane Database Syst Rev 2013; 10: CD010782.
43. Wiffen PJ, Derry S, Moore RA , et al: Antiepileptic drugs for neuro- pathic pain and fibromyalgia-an overview of Cochrane reviews. Cochrane Database Syst Rev 2013; 11: CD010567.
44. Lunn MP, Hughes RA, Wiffen PJ: Duloxetine for treating painful neu- ropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; 1: CD007115.
45. Busse JW, Ebrahim S, Connell G , et al: Systematic review and network meta-analysis of interventions for fibromyalgia: a protocol. Syst Rev 2013; 2: 18.
46.
47.
48.
49. Hoffman JM, Shah ND, Vermeulen LC, et al: Projecting future drug expenditures-2008. Am J Health Syst Pharm 2008
50. Hoffman JM, Doloresco F, Vermeulen LC, et al: Projecting future drug expenditures-2010. Am J Health Syst Pharm 2010
51. Fitzcharles MA, Faregh N, Ste-Marie PA, Shir Y: Opioid use in fibro- myalgia is associated with negative health related measures in a pro- spective cohort study. Pain Res Treat 2013; 2013: 898493.
52.
53. Suehs BT, Lauder A, Udall M, Cappelleri JC, Joshi AV, Patel NC: Impact of a pregabalin step therapy policy among medicare advantage beneficiaries. Pain Pract 2014; 14(5): 419- 26.
*
[dagger]
[double dagger]
§Altarum Institute,
doi: 10.7205/MILMED-D-13-00419
| Copyright: | (c) 2014 Association of Military Surgeons of the United States |
| Wordcount: | 6169 |
Determinants of Utilization and Cost of VHA Care by OEF/OIF Veterans Screened for Mild Traumatic Brain Injury
Adjuvant Radioactive Iodine Use Among Differentiated Thyroid Cancer Patients in the Military Health System
Advisor News
- Innovative financial literacy’s greatest hits
- Gen Z not following the typical path to retirement
- Survey finds some support for DOL fiduciary rule
- Nonprofit involvement: How do you get business and WIIFM?
- Workers still concerned about financial well-being
More Advisor NewsAnnuity News
- Brighthouse Financial Announces Completion of Reinsurance Transaction
- Corebridge Financial tallies strong annuity, life sales numbers in Q3
- Equitable hones in on annuity delivery across channels after strong Q3
- Maintaining annuity sales momentum with Gen X
- Best’s Special Report: Smaller Companies Face Cash Flow Crunch from Uptick in U.S. Life/Annuity Surrenders
More Annuity NewsHealth/Employee Benefits News
- Childbirth Can Bring Worrying Medical Bills, Even With Insurance
- What will a new Trump presidency do for health care?
- Managing the annual enrollment welcome call surge
- Promising 'support,' Aetna declares readiness to run State Health Plan
Aetna says its ready to run State Health Plan
- Pacific Prime Unveils Cost of International Health Insurance Report 2024
More Health/Employee Benefits NewsLife Insurance News
- AM Best Removes From Under Review With Developing Implications and Upgrades Credit Ratings of Merit Life Insurance Co.
- Automatic Shelf Registration Statement Form S 3ASR
- Greg Lindberg plea deal reached on federal fraud charges
- AM Best Affirms Credit Ratings of Standard Insurance Company and its Affiliate Companies, and Pacific Guardian Life Insurance Company, Limited
- WTW appoints Karen Grote as Division LOB Leader for North America Life Practice
More Life Insurance News